Limiting damage during infection: lessons from infection tolerance for novel therapeutics.

The distinction between pathogen elimination and damage limitation during infection is beginning to change perspectives on infectious disease control, and has recently led to the development of novel therapies that focus on reducing the illness caused by pathogens (‘‘damage limitation’’)rather than...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pedro F Vale, Andy Fenton, Sam P Brown
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/9cccae26b0d44df8b066c4efba79e9e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9cccae26b0d44df8b066c4efba79e9e1
record_format	dspace
spelling	oai:doaj.org-article:9cccae26b0d44df8b066c4efba79e9e12021-11-18T05:37:37ZLimiting damage during infection: lessons from infection tolerance for novel therapeutics.1544-91731545-788510.1371/journal.pbio.1001769https://doaj.org/article/9cccae26b0d44df8b066c4efba79e9e12014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24465177/?tool=EBIhttps://doaj.org/toc/1544-9173https://doaj.org/toc/1545-7885The distinction between pathogen elimination and damage limitation during infection is beginning to change perspectives on infectious disease control, and has recently led to the development of novel therapies that focus on reducing the illness caused by pathogens (‘‘damage limitation’’)rather than reducing pathogen burdens directly (‘‘pathogen elimination’’). While beneficial at the individual host level, the population consequences of these interventions remain unclear. To address this issue,we present a simple conceptual framework for damage limitation during infection that distinguishes between therapies that are either host-centric (pro-tolerance) or pathogen-centric (anti-virulence). We then draw on recent developments from the evolutionary ecology of disease tolerance to highlight some potential epidemiological and evolutionary responses of pathogens to medical interventions that target the symptoms of infection. Just as pathogens are known to evolve in response to antimicrobial and vaccination therapies, we caution that claims of ‘‘evolution-proof’’ anti-virulence interventions may be premature, and further, that in infections where virulence and transmission are linked, reducing illness without reducing pathogen burden could have non-trivial epidemiological and evolutionary consequences that require careful examination.Pedro F ValeAndy FentonSam P BrownPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Biology, Vol 12, Iss 1, p e1001769 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Pedro F Vale Andy Fenton Sam P Brown Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
description	The distinction between pathogen elimination and damage limitation during infection is beginning to change perspectives on infectious disease control, and has recently led to the development of novel therapies that focus on reducing the illness caused by pathogens (‘‘damage limitation’’)rather than reducing pathogen burdens directly (‘‘pathogen elimination’’). While beneficial at the individual host level, the population consequences of these interventions remain unclear. To address this issue,we present a simple conceptual framework for damage limitation during infection that distinguishes between therapies that are either host-centric (pro-tolerance) or pathogen-centric (anti-virulence). We then draw on recent developments from the evolutionary ecology of disease tolerance to highlight some potential epidemiological and evolutionary responses of pathogens to medical interventions that target the symptoms of infection. Just as pathogens are known to evolve in response to antimicrobial and vaccination therapies, we caution that claims of ‘‘evolution-proof’’ anti-virulence interventions may be premature, and further, that in infections where virulence and transmission are linked, reducing illness without reducing pathogen burden could have non-trivial epidemiological and evolutionary consequences that require careful examination.
format	article
author	Pedro F Vale Andy Fenton Sam P Brown
author_facet	Pedro F Vale Andy Fenton Sam P Brown
author_sort	Pedro F Vale
title	Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
title_short	Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
title_full	Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
title_fullStr	Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
title_full_unstemmed	Limiting damage during infection: lessons from infection tolerance for novel therapeutics.
title_sort	limiting damage during infection: lessons from infection tolerance for novel therapeutics.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/9cccae26b0d44df8b066c4efba79e9e1
work_keys_str_mv	AT pedrofvale limitingdamageduringinfectionlessonsfrominfectiontolerancefornoveltherapeutics AT andyfenton limitingdamageduringinfectionlessonsfrominfectiontolerancefornoveltherapeutics AT sampbrown limitingdamageduringinfectionlessonsfrominfectiontolerancefornoveltherapeutics
_version_	1718424867861168128

Limiting damage during infection: lessons from infection tolerance for novel therapeutics.

Ejemplares similares